OSAAI 2023 Northwest Allergy Forum
The Oregon Society of Allergy, Asthma & Immunology (OSAAI) 2023 program is an eight-hour event specifically designed to meet perceived unmet needs among practicing allergists, with emphasis on topics that are not covered in other formats. The OSAAI Faculty are experts in their field and will provide evidence-based, clinical topics that address major aspects of attendee’s practices and will provide attendees exposure to new content.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Oregon Society of Allergy, Asthma & Immunology (OSAAI). The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 8 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 8 contact hours.
Primary care physicians
Allied healthcare professionals.
At the end of this activity, participants should be able to:
1. Judge an appropriate clinicopathologic endpoint for therapy in EoE
2. Describe novel targets for management of severe asthma
3. Apply clinical practice guidelines to the management of patients with chronic urticaria
4. Discuss key updates in latest drug allergy practice parameter
5. Explore the role of environmental exposures in pediatric asthma
OSAAI 2023: Northwest Allergy Forum | October 13-15, 2023
Hyatt Regency | 375 NE Holladay Street | Portland, OR 97232
Friday, October 13th
5:00pm-7:00pm Registration, Exhibits & Welcome Reception
Saturday, October 14th
7:00am-7:50am Exhibits | Registration | Coffee Break
7:50am-8:00am Welcome & Introduction – Shyam Joshi, MD – President, OSAAI
Session Moderator – Shyam Joshi, MD
8:00am-9:00am Pediatric Asthma – Jessica Stern, MD, MS
9:00am-10:00am Eosinophilic Esophagitis: Clinical Care and Research Updates – Emily Clark McGowan, MD, PhD
10:00am-10:30am Coffee Break | Exhibits
10:30-11:30am Updates on Chronic Urticaria – David A. Khan, MD
11:30am-12:30pm Updates on Venom Allergy – Karen Anstey, MD
Sunday, October 15th
7:00am-8:00am Exhibits | Coffee Break
7:50am-8:00am Welcome & Introduction
Session Moderator– Melanie Wayne, OSAAI Board of Directors
8:00am-9:00am Adult Food Allergy – Emily Clark McGowan, MD, PhD
9:00am-10:00am Brought to you by the American College of Allergy, Asthma & Immunology: Advocacy Council -
Here for You & What’s on Our Horizon – Travis A. Miller, MD, FACAAI
10:00am-10:30am Coffee Break | Exhibits
10:30am-11:30am Using the 2022 Drug Allergy Parameter Update to Make Your Life Easier – David A. Khan, MD
11:30am-12:30pm Health Disparities in Allergy and Immunology – Jessica Stern, MD, MS
Disclosure Policy and Disclosures
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewer, and other individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.
Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. (Examples of ineligible companies include: Advertising, marketing, or communication firms whose clients are ineligible companies; bio-medical startups that have begun a governmental regulatory approval process; compounding pharmacies that manufacture proprietary compounds; device manufacturers or distributors; diagnostic labs that sell proprietary products; growers, distributors, manufacturers or sellers of medical foods and dietary supplements; manufacturers of health-related wearable products; pharmaceutical companies or distributors; pharmacy benefit managers; reagent manufacturers or sellers).
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.
All identified relevant financial relationships with ineligible companies have been mitigated.
Karen Anstey, MD – Speaker
Stock – 3M
Emily Clarke McGowan, MD, PhD – Speaker
Researcher – Regeneron
Consultant – Regeneron
Shyam Joshi, MD – Planner, Moderator
Advisor – Cogent, Leo Pharma, Sanofi/Regeneron
Advisory Board – Takeda
Researcher – Sanofi/Regeneron
Melanie Wayne, NP – Planner, Moderator
Advisor – CSL Behring
The following have no relevant financial relationships with ineligible companies to disclose:
David A. Khan, MD – Speaker
Travis Miller, MD – Speaker
Jessica Stern, MD, MS – Speaker
James Baker, MD - Planner
Albert Tsien, MD – Planner
Karol Anderson - Planner
- 8.00 AMA PRA Category 1 Credit™
- 8.00 Attendance
- 8.00 CBRN